deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT00255801

Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma

Phase II Trial of Doxorubicin HCl Liposome Injection (Doxil®) in Advanced Stage Cutaneous T-Cell Lymphoma Followed by Bexarotene (Targretin®)

Sponsor: Hackensack Meridian Health

Conditions Lymphoma
Interventions Targretin® (bexarotene) pegylated liposomal doxorubicin hydrochloride
Updated 11 times since 2017 Last updated: Jul 19, 2018 Started: Nov 30, 2005 Primary completion: Oct 31, 2017 Completion: Oct 31, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Lymphoma and is currently completed. Hackensack Meridian Health leads this study, which shows 11 recorded versions since 2005 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Nov 2017 · 9 months · monthly snapshotActive Not Recruiting~Nov 2017 – ~Jun 2018 · 7 months · monthly snapshotCompleted~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshotCompleted~Sep 2018 – ~Jun 2019 · 9 months · monthly snapshotCompleted~Jun 2019 – ~Jan 2021 · 19 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshotCompleted~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotCompleted~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 21 months · monthly snapshotCompleted

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

  5. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE2

▶ Show 6 earlier versions

  1. Jun 2019 — Jan 2021 [monthly]

    Completed PHASE2

  2. Sep 2018 — Jun 2019 [monthly]

    Completed PHASE2

  3. Jun 2018 — Sep 2018 [monthly]

    Completed PHASE2

  4. Nov 2017 — Jun 2018 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. Feb 2017 — Nov 2017 [monthly]

    Active Not Recruiting PHASE2

  6. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hackensack Meridian Health
  • M.D. Anderson Cancer Center
  • Memorial Sloan Kettering Cancer Center
  • NYU Langone Health
  • National Cancer Institute (NCI)
  • Roswell Park Cancer Institute
  • Tibotec Pharmaceutical Limited
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations